Calibrate’s Post

Last month, I published an article in my newsletter "Breaking the Healthcare Rules" about Ozempic as a weight-loss drug. As expected, the article drew lots of interest and sparked significant conversation here on LinkedIn. While GLP-1 medications have the potential to help our nation fight obesity, they carry an oversized price tag: upwards of $16,000 per year. With that in mind, I’d like to ask for your thoughts on obesity in America. My new poll contains three multiple-choice questions and takes most users less than 2 minutes to complete. Responses are confidential and cumulative totals will be shared next month. For results of last month's poll, check out the comments. #healthcare #healthcareonlinkedin #opinionpoll

Medical weight loss refers to a structured weight management program that is supervised by medical professionals, typically including physicians and other healthcare providers. It focuses on achieving weight loss and improving overall health through evidence-based strategies and interventions. These programs are tailored to individual needs and often involve a comprehensive approach that combines diet, physical activity, behavior modification, and medication or other medical interventions. They are designed to address underlying factors contributing to weight gain or difficulty losing weight, such as hormonal imbalances, metabolic disorders, or certain medical conditions. https://lnkd.in/eqiesDdB #ApexHormoneHealth #HormoneReplacement #TestosteroneReplacement

⚖️Understanding weight loss with weight loss medications! 💊When people suffering from #obesity use a medicine called tirzepatide, they can lose a lot of weight, but e new study shows something important for these people! Those who kept taking tirzepatide for more than a year continued to lose weight, but, those who stopped taking it and switched to a fake pill (placebo) started to gain weight back again! 🔬For the professionals out there: Among adults with obesity who had previously lost weight (21 percent mean weight reduction) during a 36-week, open-label trial of tirzepatide, those randomly assigned to continue tirzepatide for 52 weeks experienced additional weight loss, whereas those assigned to placebo partially regained (-5.5 versus +14 percent mean weight change, respectively) 🚨This study tells us that to keep weight off with drugs, it might be necessary to takethem for a long time, which is something unsustainable and not so economic and healthy probably! 📖Read original study: https://lnkd.in/eYrSU58j #WeightLoss #Tirzepatide #StayHealthy

Active B12 Test Market size was valued at USD 182.23 Mn. in 2023 and the Active B12 Test revenue is expected to grow at a CAGR of 24.7% from 2024 to 2030, reaching nearly USD 854.45 Mn. by 2030. The Active B12 Test Market is witnessing remarkable growth as awareness of the importance of vitamin B12 in overall health rises. Active B12 tests offer accurate detection of B12 deficiency, which is crucial for preventing serious health issues such as anemia, neuropathy, and cognitive impairments. With advancements in diagnostic technology, healthcare providers can now offer more precise and timely interventions. Stay informed about the latest trends and innovations in this vital sector. Request for sample Request:https://lnkd.in/d9nsWJkA #ActiveB12Test #HealthcareInnovation #DiagnosticTesting #VitaminB12 #HealthAndWellness #MedicalAdvancements

Excited to explore the intricate details of weight management goals in pharmacological therapy for individuals with diabetes! These goals are vital for achieving lasting weight loss, enhancing insulin sensitivity, and improving overall health. Choosing the right pharmacological agent in clinical settings demands a patient-centered approach, taking into account factors like comorbidities, medication history, and patient preferences. Eager to apply these insights to enhance diabetes management outcomes! #DiabetesManagement #WeightLossGoals #PatientCenteredCare

When it comes to managing patients living with obesity, we’ve made no secret of our belief that a holistic approach is the best option. And we’ve got the data to prove it. In a 90-day evaluation, patients using GLP-1s who took advantage of the Numan app and our personalised behavioural coaching were associated with 36% more weight loss compared to those just taking the medication. GLP-1 medications have the potential to help people on their weight loss journeys – but when they make behavioural changes alongside these medicines, the combined results are significant. Our app gives patients the tools they need to make changes, set goals and easily track their progress. Patients can also access behavioural coaching from behaviour change experts, nutritionists and exercise physiologists, who offer tailored advice on how to hit their target. #health #weightloss #medicine #healthcoaching #obesity

**Do I stop taking anti-obesity medication once I reach my goal weight?** My name is Dr. Nikita Shah, and I’m an obesity medicine physician in Orlando, FL No, we do not stop taking anti-obesity medication once goal weight is reached. Semaglutide (GLP1A aka Ozempic or Wegovy) or Tirzepatitde (GLP1A/GIP aka Mounjaro or Zepbound) and other antiobesity medications (eg: Contrave, Qsymia) are studied and designed to be taken long term, like any other medication for chronic conditions just like diabetes, hypertension, and hypothyroidism. Obesity is a chronic, relapsing medical condition. This means that if we stop treatment, we are prone to weight regain. AOM is a great tool to maintain during the weight maintenance phase of weight care. Also, the good news is that with the treatment of obesity using medication + lifestyle changes, we can successfully improve a person’s quality of life and health outcomes.😊 To learn more visit: weight-sense.com #weightlossjourney #weightlossmotivation #antiobesitymedication #weightsense

The Employers' Guide to GLP-1s is out! GLP-1s are now among the top-cost drugs for employers. To help HR and benefits leaders navigate the evolving landscape of GLP-1s for weight loss, check out this guide that uncovers the latest evidence behind these medications, why they may not be everyone, and the importance of a multidisciplinary, stepped approach to obesity care. Download the guide here: https://lnkd.in/g4-PWx8J

A study recently published in Diabetes, Obesity and Metabolism showed that oral semaglutide 7 and 14 mg resulted in greater time spent with HbA1c less than 7.0% and a greater likelihood of achieving and maintaining HbA1c less than 7.0% versus oral comparators. New research and medications, including weight-loss drugs, keep advancing diabetes care. But there needs to be synergy between physician oversight of medication and symptoms and a patient’s commitment to lifestyle changes. My Diabetes Tutor (MDT) can help. With the virtual diabetes education and remote patient monitoring provided by MDT, the likelihood of complications is significantly reduced. Our certified nurse educators help patients navigate the behaviors associated with poor diabetes management and provide personalized coaching and support for issues that arise during the diabetes journey. Find out how MTD’s program can be part of your patients’ diabetes management team: https://buff.ly/3sf9m28 #diabetes #telehealth #diabetespatientmanagement

In a world where traditional healthcare often falls short in addressing the diverse and individualized needs of patients and where the use of GLP-1 medications is widespread and unguided, it's crucial to acknowledge that it is not a one-size-fits-all approach. Using these medications without proper guidance and follow-up can lead to suboptimal results. Zone.Health's offers evidence-based solutions that overcome the limitations of traditional healthcare. Today, we're thrilled to share the first clinical outcome report from Zone.Health, and the results are nothing short of extraordinary: - 8% weight loss at the 3 months mark - 13% weight loss at the 6 months mark - 20% weight loss at the 9 months mark - 95% of members improved at least two metabolic markers (improved lipid profile, improved liver health and significant reductions in Fat Mass. Impressively, 79% of prediabetes cases reversed their HbA1c back to normal (avg. HbA1c of 5.39) and improved their metabolic profile within only 3 months. At the 26-week mark, Zone.Health's outcomes surpassed published STEP-4, RCTs, and RWE results using similar medications. Attaching the full report for your reference, let me know what do you think about these results. Does digital health play an important role in advanced therapy for obesity management? Zone.Health Ihsan Almarzooqi Ali Hashemi Zeina A. #glp1 #digitalhealth #ZoneHealth #lifestylechanges